| 001 | 825208 | ||
| 005 | 20210129225238.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/now058 |2 DOI |
| 024 | 7 | _ | |a WOS:000384005900008 |2 WOS |
| 024 | 7 | _ | |a altmetric:6908275 |2 altmetric |
| 024 | 7 | _ | |a pmid:27106405 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-07679 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |0 P:(DE-HGF)0 |a Albert, N. L. |b 0 |e Corresponding author |
| 245 | _ | _ | |a Response Assessment in Neuro-Oncology (RANO) Working Group and European Association for Neuro-Oncology (EANO): Recommendations for the Clinical Use of PET Imaging in Gliomas |
| 260 | _ | _ | |a Oxford |b Oxford Univ. Press |c 2016 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1483605335_4023 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 520 | _ | _ | |a This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) and amino acid tracers (11C-MET, 18F-FET, and 18F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas. |
| 536 | _ | _ | |0 G:(DE-HGF)POF3-572 |a 572 - (Dys-)function and Plasticity (POF3-572) |c POF3-572 |f POF III |x 0 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Weller, M. |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Suchorska, B. |b 2 |
| 700 | 1 | _ | |0 P:(DE-Juel1)143792 |a Galldiks, Norbert |b 3 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Soffietti, R. |b 4 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kim, M. M. |b 5 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a La Fugére, C. |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Pope, W. |b 7 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Law, I. |b 8 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Arbizu, J. |b 9 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Chamberlain, M. |b 10 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Vogelbaum, M. A. |b 11 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Ellingson, B. M. |b 12 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Tonn, J. C. |b 13 |e Corresponding author |
| 773 | _ | _ | |0 PERI:(DE-600)2094060-9 |a 10.1093/neuonc/now058 |n 9 |p 1199 - 1208 |t Neuro-Oncology |v 18 |x 1522-8517 |y 2016 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:825208 |p VDB |
| 910 | 1 | _ | |0 I:(DE-588b)5008462-8 |6 P:(DE-Juel1)143792 |a Forschungszentrum Jülich |b 3 |k FZJ |
| 913 | 1 | _ | |0 G:(DE-HGF)POF3-572 |1 G:(DE-HGF)POF3-570 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l Decoding the Human Brain |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0400 |2 StatID |a Allianz-Lizenz / DFG |
| 915 | _ | _ | |0 StatID:(DE-HGF)0420 |2 StatID |a Nationallizenz |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b NEURO-ONCOLOGY : 2015 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |
| 915 | _ | _ | |0 StatID:(DE-HGF)0310 |2 StatID |a DBCoverage |b NCBI Molecular Biology Database |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |0 StatID:(DE-HGF)0111 |2 StatID |a WoS |b Science Citation Index Expanded |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |0 StatID:(DE-HGF)9905 |2 StatID |a IF >= 5 |b NEURO-ONCOLOGY : 2015 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::